End-of-life Decision in Korea

Article information

J Korean Med Assoc. 2008;51(6):524-529
Publication date (electronic) : 2008 June 30
doi : https://doi.org/10.5124/jkma.2008.51.6.524
Department of Internal Medicine, Seoul National University College of Medicine, Korea. heo1013@snu.ac.kr

Abstract

There are more than 65,000 cancer deaths per year in Korea. To what extent should we continue aggressive treatment in terminal patients? In the course of clinical care of a critically ill patient it may become clear that the patient is inevitably dying, the goal of medical treatment should not be to prolong the dying process without benefit to the patient or to others. Further intervention which will do no more than prolong the active dying process is often described as "futile." Even though hospice is widely accepted in Korea, there is still controversy about withholding or withdrawing life-sustaining treatment. Conflicts between the parties may interrupt satisfactory decision-making and adversely affect patient care, family satisfaction, and physician-clinical team functioning. When further intervention to prolong the life of a patient becomes futile, physicians have an obligation to shift the intent of care toward comfort and closure. However, there are necessary value judgments involved in coming to the assessment of futility. In this context, Korean society needs consensus agreement on futility issue, based on our own social values.

References

2. Yun YH, Kwak M, Park SM, Kim S, Choi JS, Lim HY, Lee CG, Choi YS, Hong YS, Kim SY, Heo DS. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007. 72164–171.
3. Keam BS, Oh DY, Lee SH, Kim DW, Kim MR, Im SA, Kim TY, Bang YJ, Heo DS. Aggressiveness of cancer-care near the end-of-life in Korea. Japanese Journal of Clinical On-cology 2008. 38381–386.
4. Oh DY, Kim JE, Lee CH, Lim JS, Jung KH, Heo DS, Bang YJ, Kim NK. Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer 2004. 1001961–1966.

Article information Continued